Oncology Institute (TOI) Stock Overview
An oncology company, provides various medical oncology services in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
TOI Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
The Oncology Institute, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.40 |
| 52 Week High | US$4.50 |
| 52 Week Low | US$0.13 |
| Beta | 0.11 |
| 1 Month Change | -8.85% |
| 3 Month Change | 4.62% |
| 1 Year Change | 842.35% |
| 3 Year Change | -43.33% |
| 5 Year Change | -66.50% |
| Change since IPO | -64.95% |
Recent News & Updates
Recent updates
The Oncology Institute: A Promising Company In A Growing Sector
Aug 19The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 30% But Many Are Still Ignoring The Company
Jul 15
Value Based Care Contracts Will Unlock Future Oncology Demand
New value-based care contracts and expanded partnerships are driving sustained growth and enhancing recurring revenue in a shifting oncology market.A Piece Of The Puzzle Missing From The Oncology Institute, Inc.'s (NASDAQ:TOI) 161% Share Price Climb
Apr 18Market Cool On The Oncology Institute, Inc.'s (NASDAQ:TOI) Revenues Pushing Shares 28% Lower
Mar 04The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 195% But Many Are Still Ignoring The Company
Jan 18A Piece Of The Puzzle Missing From The Oncology Institute, Inc.'s (NASDAQ:TOI) 28% Share Price Climb
Jul 19The Oncology Institute, Inc. (NASDAQ:TOI) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny
May 05Not Many Are Piling Into The Oncology Institute, Inc. (NASDAQ:TOI) Stock Yet As It Plummets 28%
Mar 21Is Oncology Institute (NASDAQ:TOI) A Risky Investment?
Mar 05The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 49% But Many Are Still Ignoring The Company
Nov 10Shareholder Returns
| TOI | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -10.3% | 0.2% | 0.01% |
| 1Y | 842.4% | -28.1% | 15.7% |
Return vs Industry: TOI exceeded the US Healthcare industry which returned -27.8% over the past year.
Return vs Market: TOI exceeded the US Market which returned 15.8% over the past year.
Price Volatility
| TOI volatility | |
|---|---|
| TOI Average Weekly Movement | 12.6% |
| Healthcare Industry Average Movement | 6.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TOI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TOI's weekly volatility has decreased from 18% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 825 | Dan Virnich | theoncologyinstitute.com |
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance services.
The Oncology Institute, Inc. Fundamentals Summary
| TOI fundamental statistics | |
|---|---|
| Market cap | US$317.92m |
| Earnings (TTM) | -US$54.12m |
| Revenue (TTM) | US$424.38m |
Is TOI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TOI income statement (TTM) | |
|---|---|
| Revenue | US$424.38m |
| Cost of Revenue | US$360.62m |
| Gross Profit | US$63.75m |
| Other Expenses | US$117.88m |
| Earnings | -US$54.12m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.58 |
| Gross Margin | 15.02% |
| Net Profit Margin | -12.75% |
| Debt/Equity Ratio | -838.5% |
How did TOI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/31 21:19 |
| End of Day Share Price | 2025/08/29 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
The Oncology Institute, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yuan Zhi | B. Riley Securities, Inc. |
| David Larsen | BTIG |
| Alexander Draper | Guggenheim Securities, LLC |